Five-treatment radiation regimen poised to become standard of care, phase III data show

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Men with intermediate-risk prostate cancer can receive a complete course of radiation in just five treatments—rather than the typical 20 to 28—while maintaining excellent cancer control and improving quality of life, according to results of an international phase III trial conducted by Rodney J. Ellis. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login